From cancer metabolism to new biomarkers and drug targets
Great interest is presently given to the analysis of metabolic changes that take place specifically in cancer cells. In this review we summarize the alterations in glycolysis, glutamine utilization, fatty acid synthesis and mitochondrial function that have been reported to occur in cancer cells and...
Gespeichert in:
| Veröffentlicht in: | Biotechnology advances 2012, Vol.30 (1), p.30-51 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 51 |
|---|---|
| container_issue | 1 |
| container_start_page | 30 |
| container_title | Biotechnology advances |
| container_volume | 30 |
| creator | Chiaradonna, F. Moresco, R.M. Airoldi, C. Gaglio, D. Palorini, R. Nicotra, F. Messa, C. Alberghina, L. |
| description | Great interest is presently given to the analysis of metabolic changes that take place specifically in cancer cells. In this review we summarize the alterations in glycolysis, glutamine utilization, fatty acid synthesis and mitochondrial function that have been reported to occur in cancer cells and in human tumors. We then propose considering cancer as a system-level disease and argue how two hallmarks of cancer, enhanced cell proliferation and evasion from apoptosis, may be evaluated as system-level properties, and how this perspective is going to modify drug discovery.
Given the relevance of the analysis of metabolism both for studies on the molecular basis of cancer cell phenotype and for clinical applications, the more relevant technologies for this purpose, from metabolome and metabolic flux analysis in cells by Nuclear Magnetic Resonance and Mass Spectrometry technologies to positron emission tomography on patients, are analyzed.
The perspectives offered by specific changes in metabolism for a new drug discovery strategy for cancer are discussed and a survey of the industrial activity already going on in the field is reported. |
| doi_str_mv | 10.1016/j.biotechadv.2011.07.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_920799230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0734975011001169</els_id><sourcerecordid>916527568</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-25f02c6a813a0905d6d2868c28bbf3f612dd0f86eb58d0d24b1c78398150ee0d3</originalsourceid><addsrcrecordid>eNqFkctOHDEQRS0UBMPAL0TeJZvuVNnj1zJB4SEhZQNry21XQ0-mp4ndA8rfx2gg2YVVbU7VLd3DGEdoEVB_WbfdMM0UH0J6agUgtmBaAH3AFmiNbNA694EtwMhV44yCY3ZSyhoAFSh5xI4FWhAK5IK5izyNPIZtpMxHmkM3bYYy8nniW3rmNWYM-SflwsM28ZR393wO-Z7mcsoO-7ApdPY6l-zu4vvt-VVz8-Py-vzrTRNX0s6NUD2IqINFGcCBSjoJq20Utut62WsUKUFvNXXKJkhi1WE0VjpbfyWCJJfs0_7uY55-7ajMfhxKpM0mbGnaFe8EGOeEhPdJ1EoYpW0lP_-XRG1QrjTWp5fM7tGYp1Iy9f4xD7WT3x7Bv8jwa_9Phn-R4cH4KqOufnxN2XUjpb-Lb-1X4NseoNrf00DZlzhQVZGGTHH2aRreT_kD11CeMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1671346181</pqid></control><display><type>article</type><title>From cancer metabolism to new biomarkers and drug targets</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Chiaradonna, F. ; Moresco, R.M. ; Airoldi, C. ; Gaglio, D. ; Palorini, R. ; Nicotra, F. ; Messa, C. ; Alberghina, L.</creator><creatorcontrib>Chiaradonna, F. ; Moresco, R.M. ; Airoldi, C. ; Gaglio, D. ; Palorini, R. ; Nicotra, F. ; Messa, C. ; Alberghina, L.</creatorcontrib><description>Great interest is presently given to the analysis of metabolic changes that take place specifically in cancer cells. In this review we summarize the alterations in glycolysis, glutamine utilization, fatty acid synthesis and mitochondrial function that have been reported to occur in cancer cells and in human tumors. We then propose considering cancer as a system-level disease and argue how two hallmarks of cancer, enhanced cell proliferation and evasion from apoptosis, may be evaluated as system-level properties, and how this perspective is going to modify drug discovery.
Given the relevance of the analysis of metabolism both for studies on the molecular basis of cancer cell phenotype and for clinical applications, the more relevant technologies for this purpose, from metabolome and metabolic flux analysis in cells by Nuclear Magnetic Resonance and Mass Spectrometry technologies to positron emission tomography on patients, are analyzed.
The perspectives offered by specific changes in metabolism for a new drug discovery strategy for cancer are discussed and a survey of the industrial activity already going on in the field is reported.</description><identifier>ISSN: 0734-9750</identifier><identifier>EISSN: 1873-1899</identifier><identifier>DOI: 10.1016/j.biotechadv.2011.07.006</identifier><identifier>PMID: 21802503</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Animals ; Antineoplastic Agents - pharmacology ; Apoptosis ; Biomarkers, Tumor - metabolism ; Cancer ; Drug discovery ; Drugs ; Fatty acids ; Humans ; Mass spectrometry ; Metabolic Networks and Pathways ; Metabolism ; Molecular Targeted Therapy ; Neoplasms - drug therapy ; Neoplasms - metabolism ; NMR ; Patients ; PET ; Systems biology ; Tumors</subject><ispartof>Biotechnology advances, 2012, Vol.30 (1), p.30-51</ispartof><rights>2011 Elsevier Inc.</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-25f02c6a813a0905d6d2868c28bbf3f612dd0f86eb58d0d24b1c78398150ee0d3</citedby><cites>FETCH-LOGICAL-c438t-25f02c6a813a0905d6d2868c28bbf3f612dd0f86eb58d0d24b1c78398150ee0d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.biotechadv.2011.07.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21802503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiaradonna, F.</creatorcontrib><creatorcontrib>Moresco, R.M.</creatorcontrib><creatorcontrib>Airoldi, C.</creatorcontrib><creatorcontrib>Gaglio, D.</creatorcontrib><creatorcontrib>Palorini, R.</creatorcontrib><creatorcontrib>Nicotra, F.</creatorcontrib><creatorcontrib>Messa, C.</creatorcontrib><creatorcontrib>Alberghina, L.</creatorcontrib><title>From cancer metabolism to new biomarkers and drug targets</title><title>Biotechnology advances</title><addtitle>Biotechnol Adv</addtitle><description>Great interest is presently given to the analysis of metabolic changes that take place specifically in cancer cells. In this review we summarize the alterations in glycolysis, glutamine utilization, fatty acid synthesis and mitochondrial function that have been reported to occur in cancer cells and in human tumors. We then propose considering cancer as a system-level disease and argue how two hallmarks of cancer, enhanced cell proliferation and evasion from apoptosis, may be evaluated as system-level properties, and how this perspective is going to modify drug discovery.
Given the relevance of the analysis of metabolism both for studies on the molecular basis of cancer cell phenotype and for clinical applications, the more relevant technologies for this purpose, from metabolome and metabolic flux analysis in cells by Nuclear Magnetic Resonance and Mass Spectrometry technologies to positron emission tomography on patients, are analyzed.
The perspectives offered by specific changes in metabolism for a new drug discovery strategy for cancer are discussed and a survey of the industrial activity already going on in the field is reported.</description><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Drug discovery</subject><subject>Drugs</subject><subject>Fatty acids</subject><subject>Humans</subject><subject>Mass spectrometry</subject><subject>Metabolic Networks and Pathways</subject><subject>Metabolism</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>NMR</subject><subject>Patients</subject><subject>PET</subject><subject>Systems biology</subject><subject>Tumors</subject><issn>0734-9750</issn><issn>1873-1899</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctOHDEQRS0UBMPAL0TeJZvuVNnj1zJB4SEhZQNry21XQ0-mp4ndA8rfx2gg2YVVbU7VLd3DGEdoEVB_WbfdMM0UH0J6agUgtmBaAH3AFmiNbNA694EtwMhV44yCY3ZSyhoAFSh5xI4FWhAK5IK5izyNPIZtpMxHmkM3bYYy8nniW3rmNWYM-SflwsM28ZR393wO-Z7mcsoO-7ApdPY6l-zu4vvt-VVz8-Py-vzrTRNX0s6NUD2IqINFGcCBSjoJq20Utut62WsUKUFvNXXKJkhi1WE0VjpbfyWCJJfs0_7uY55-7ajMfhxKpM0mbGnaFe8EGOeEhPdJ1EoYpW0lP_-XRG1QrjTWp5fM7tGYp1Iy9f4xD7WT3x7Bv8jwa_9Phn-R4cH4KqOufnxN2XUjpb-Lb-1X4NseoNrf00DZlzhQVZGGTHH2aRreT_kD11CeMw</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Chiaradonna, F.</creator><creator>Moresco, R.M.</creator><creator>Airoldi, C.</creator><creator>Gaglio, D.</creator><creator>Palorini, R.</creator><creator>Nicotra, F.</creator><creator>Messa, C.</creator><creator>Alberghina, L.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U5</scope><scope>8FD</scope><scope>L7M</scope><scope>7X8</scope><scope>7QO</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>2012</creationdate><title>From cancer metabolism to new biomarkers and drug targets</title><author>Chiaradonna, F. ; Moresco, R.M. ; Airoldi, C. ; Gaglio, D. ; Palorini, R. ; Nicotra, F. ; Messa, C. ; Alberghina, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-25f02c6a813a0905d6d2868c28bbf3f612dd0f86eb58d0d24b1c78398150ee0d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Drug discovery</topic><topic>Drugs</topic><topic>Fatty acids</topic><topic>Humans</topic><topic>Mass spectrometry</topic><topic>Metabolic Networks and Pathways</topic><topic>Metabolism</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>NMR</topic><topic>Patients</topic><topic>PET</topic><topic>Systems biology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiaradonna, F.</creatorcontrib><creatorcontrib>Moresco, R.M.</creatorcontrib><creatorcontrib>Airoldi, C.</creatorcontrib><creatorcontrib>Gaglio, D.</creatorcontrib><creatorcontrib>Palorini, R.</creatorcontrib><creatorcontrib>Nicotra, F.</creatorcontrib><creatorcontrib>Messa, C.</creatorcontrib><creatorcontrib>Alberghina, L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Technology Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Biotechnology advances</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiaradonna, F.</au><au>Moresco, R.M.</au><au>Airoldi, C.</au><au>Gaglio, D.</au><au>Palorini, R.</au><au>Nicotra, F.</au><au>Messa, C.</au><au>Alberghina, L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>From cancer metabolism to new biomarkers and drug targets</atitle><jtitle>Biotechnology advances</jtitle><addtitle>Biotechnol Adv</addtitle><date>2012</date><risdate>2012</risdate><volume>30</volume><issue>1</issue><spage>30</spage><epage>51</epage><pages>30-51</pages><issn>0734-9750</issn><eissn>1873-1899</eissn><abstract>Great interest is presently given to the analysis of metabolic changes that take place specifically in cancer cells. In this review we summarize the alterations in glycolysis, glutamine utilization, fatty acid synthesis and mitochondrial function that have been reported to occur in cancer cells and in human tumors. We then propose considering cancer as a system-level disease and argue how two hallmarks of cancer, enhanced cell proliferation and evasion from apoptosis, may be evaluated as system-level properties, and how this perspective is going to modify drug discovery.
Given the relevance of the analysis of metabolism both for studies on the molecular basis of cancer cell phenotype and for clinical applications, the more relevant technologies for this purpose, from metabolome and metabolic flux analysis in cells by Nuclear Magnetic Resonance and Mass Spectrometry technologies to positron emission tomography on patients, are analyzed.
The perspectives offered by specific changes in metabolism for a new drug discovery strategy for cancer are discussed and a survey of the industrial activity already going on in the field is reported.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>21802503</pmid><doi>10.1016/j.biotechadv.2011.07.006</doi><tpages>22</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0734-9750 |
| ispartof | Biotechnology advances, 2012, Vol.30 (1), p.30-51 |
| issn | 0734-9750 1873-1899 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_920799230 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Antineoplastic Agents - pharmacology Apoptosis Biomarkers, Tumor - metabolism Cancer Drug discovery Drugs Fatty acids Humans Mass spectrometry Metabolic Networks and Pathways Metabolism Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - metabolism NMR Patients PET Systems biology Tumors |
| title | From cancer metabolism to new biomarkers and drug targets |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T21%3A17%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=From%20cancer%20metabolism%20to%20new%20biomarkers%20and%20drug%20targets&rft.jtitle=Biotechnology%20advances&rft.au=Chiaradonna,%20F.&rft.date=2012&rft.volume=30&rft.issue=1&rft.spage=30&rft.epage=51&rft.pages=30-51&rft.issn=0734-9750&rft.eissn=1873-1899&rft_id=info:doi/10.1016/j.biotechadv.2011.07.006&rft_dat=%3Cproquest_cross%3E916527568%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1671346181&rft_id=info:pmid/21802503&rft_els_id=S0734975011001169&rfr_iscdi=true |